nodes	percent_of_prediction	percent_of_DWPC	metapath
Halofantrine—CYP3A5—Sorafenib—thyroid cancer	0.169	0.237	CbGbCtD
Halofantrine—CYP2C8—Sorafenib—thyroid cancer	0.162	0.228	CbGbCtD
Halofantrine—CYP3A4—Vandetanib—thyroid cancer	0.109	0.153	CbGbCtD
Halofantrine—CYP2D6—Sorafenib—thyroid cancer	0.103	0.145	CbGbCtD
Halofantrine—CYP3A4—Sorafenib—thyroid cancer	0.0657	0.0924	CbGbCtD
Halofantrine—CYP2D6—Doxorubicin—thyroid cancer	0.0627	0.0882	CbGbCtD
Halofantrine—CYP3A4—Doxorubicin—thyroid cancer	0.0399	0.0561	CbGbCtD
Halofantrine—Hypertensive crisis—Vandetanib—thyroid cancer	0.0313	0.108	CcSEcCtD
Halofantrine—Hypertensive crisis—Sorafenib—thyroid cancer	0.0211	0.0731	CcSEcCtD
Halofantrine—Altered state of consciousness—Vandetanib—thyroid cancer	0.0188	0.0652	CcSEcCtD
Halofantrine—Platelet count decreased—Vandetanib—thyroid cancer	0.0146	0.0506	CcSEcCtD
Halofantrine—Depressed level of consciousness—Vandetanib—thyroid cancer	0.00839	0.0291	CcSEcCtD
Halofantrine—Pollakiuria—Vandetanib—thyroid cancer	0.00504	0.0174	CcSEcCtD
Halofantrine—Stomatitis—Vandetanib—thyroid cancer	0.00474	0.0164	CcSEcCtD
Halofantrine—Visual impairment—Vandetanib—thyroid cancer	0.0042	0.0146	CcSEcCtD
Halofantrine—Arrhythmia—Vandetanib—thyroid cancer	0.0039	0.0135	CcSEcCtD
Halofantrine—Cough—Vandetanib—thyroid cancer	0.00331	0.0115	CcSEcCtD
Halofantrine—Convulsion—Vandetanib—thyroid cancer	0.00329	0.0114	CcSEcCtD
Halofantrine—Arthralgia—Vandetanib—thyroid cancer	0.00323	0.0112	CcSEcCtD
Halofantrine—Chest pain—Vandetanib—thyroid cancer	0.00323	0.0112	CcSEcCtD
Halofantrine—Stomatitis—Sorafenib—thyroid cancer	0.0032	0.0111	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00282	0.00978	CcSEcCtD
Halofantrine—Paraesthesia—Vandetanib—thyroid cancer	0.00278	0.00964	CcSEcCtD
Halofantrine—Tinnitus—Sorafenib—thyroid cancer	0.00274	0.00951	CcSEcCtD
Halofantrine—Dyspepsia—Vandetanib—thyroid cancer	0.00273	0.00945	CcSEcCtD
Halofantrine—Decreased appetite—Vandetanib—thyroid cancer	0.00269	0.00934	CcSEcCtD
Halofantrine—Fatigue—Vandetanib—thyroid cancer	0.00267	0.00926	CcSEcCtD
Halofantrine—Rigors—Epirubicin—thyroid cancer	0.00265	0.00919	CcSEcCtD
Halofantrine—Constipation—Vandetanib—thyroid cancer	0.00265	0.00918	CcSEcCtD
Halofantrine—Arrhythmia—Sorafenib—thyroid cancer	0.00263	0.00911	CcSEcCtD
Halofantrine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00253	0.00878	CcSEcCtD
Halofantrine—Rigors—Doxorubicin—thyroid cancer	0.00245	0.0085	CcSEcCtD
Halofantrine—Abdominal pain—Vandetanib—thyroid cancer	0.00245	0.00849	CcSEcCtD
Halofantrine—Cough—Sorafenib—thyroid cancer	0.00224	0.00775	CcSEcCtD
Halofantrine—Asthenia—Vandetanib—thyroid cancer	0.00222	0.0077	CcSEcCtD
Halofantrine—Pruritus—Vandetanib—thyroid cancer	0.00219	0.0076	CcSEcCtD
Halofantrine—Myalgia—Sorafenib—thyroid cancer	0.00218	0.00756	CcSEcCtD
Halofantrine—Arthralgia—Sorafenib—thyroid cancer	0.00218	0.00756	CcSEcCtD
Halofantrine—Diarrhoea—Vandetanib—thyroid cancer	0.00212	0.00735	CcSEcCtD
Halofantrine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00209	0.00724	CcSEcCtD
Halofantrine—Dizziness—Vandetanib—thyroid cancer	0.00205	0.0071	CcSEcCtD
Halofantrine—Anorexia—Sorafenib—thyroid cancer	0.00199	0.00691	CcSEcCtD
Halofantrine—Vomiting—Vandetanib—thyroid cancer	0.00197	0.00683	CcSEcCtD
Halofantrine—Rash—Vandetanib—thyroid cancer	0.00195	0.00677	CcSEcCtD
Halofantrine—Dermatitis—Vandetanib—thyroid cancer	0.00195	0.00676	CcSEcCtD
Halofantrine—Headache—Vandetanib—thyroid cancer	0.00194	0.00673	CcSEcCtD
Halofantrine—Pulmonary oedema—Epirubicin—thyroid cancer	0.00193	0.00668	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.0019	0.0066	CcSEcCtD
Halofantrine—Abnormal vision—Epirubicin—thyroid cancer	0.00189	0.00654	CcSEcCtD
Halofantrine—Nausea—Vandetanib—thyroid cancer	0.00184	0.00638	CcSEcCtD
Halofantrine—Dyspepsia—Sorafenib—thyroid cancer	0.00184	0.00638	CcSEcCtD
Halofantrine—Decreased appetite—Sorafenib—thyroid cancer	0.00182	0.0063	CcSEcCtD
Halofantrine—Fatigue—Sorafenib—thyroid cancer	0.0018	0.00625	CcSEcCtD
Halofantrine—Constipation—Sorafenib—thyroid cancer	0.00179	0.00619	CcSEcCtD
Halofantrine—Pulmonary oedema—Doxorubicin—thyroid cancer	0.00178	0.00618	CcSEcCtD
Halofantrine—Abnormal vision—Doxorubicin—thyroid cancer	0.00175	0.00606	CcSEcCtD
Halofantrine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00171	0.00592	CcSEcCtD
Halofantrine—Urticaria—Sorafenib—thyroid cancer	0.00166	0.00575	CcSEcCtD
Halofantrine—Abdominal pain—Sorafenib—thyroid cancer	0.00165	0.00573	CcSEcCtD
Halofantrine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.0016	0.00556	CcSEcCtD
Halofantrine—Face oedema—Epirubicin—thyroid cancer	0.00152	0.00526	CcSEcCtD
Halofantrine—Asthenia—Sorafenib—thyroid cancer	0.0015	0.0052	CcSEcCtD
Halofantrine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00148	0.00514	CcSEcCtD
Halofantrine—Pruritus—Sorafenib—thyroid cancer	0.00148	0.00513	CcSEcCtD
Halofantrine—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00144	0.00497	CcSEcCtD
Halofantrine—Diarrhoea—Sorafenib—thyroid cancer	0.00143	0.00496	CcSEcCtD
Halofantrine—Face oedema—Doxorubicin—thyroid cancer	0.0014	0.00487	CcSEcCtD
Halofantrine—Dizziness—Sorafenib—thyroid cancer	0.00138	0.00479	CcSEcCtD
Halofantrine—Abdominal distension—Epirubicin—thyroid cancer	0.00137	0.00474	CcSEcCtD
Halofantrine—Vomiting—Sorafenib—thyroid cancer	0.00133	0.00461	CcSEcCtD
Halofantrine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00133	0.0046	CcSEcCtD
Halofantrine—Rash—Sorafenib—thyroid cancer	0.00132	0.00457	CcSEcCtD
Halofantrine—Dermatitis—Sorafenib—thyroid cancer	0.00132	0.00456	CcSEcCtD
Halofantrine—Headache—Sorafenib—thyroid cancer	0.00131	0.00454	CcSEcCtD
Halofantrine—Abdominal distension—Doxorubicin—thyroid cancer	0.00127	0.00439	CcSEcCtD
Halofantrine—Pollakiuria—Epirubicin—thyroid cancer	0.00126	0.00435	CcSEcCtD
Halofantrine—Nausea—Sorafenib—thyroid cancer	0.00124	0.0043	CcSEcCtD
Halofantrine—Stomatitis—Epirubicin—thyroid cancer	0.00118	0.00409	CcSEcCtD
Halofantrine—Pollakiuria—Doxorubicin—thyroid cancer	0.00116	0.00402	CcSEcCtD
Halofantrine—Stomatitis—Doxorubicin—thyroid cancer	0.00109	0.00379	CcSEcCtD
Halofantrine—Visual impairment—Epirubicin—thyroid cancer	0.00105	0.00363	CcSEcCtD
Halofantrine—Tinnitus—Epirubicin—thyroid cancer	0.00101	0.00351	CcSEcCtD
Halofantrine—Chills—Epirubicin—thyroid cancer	0.000976	0.00338	CcSEcCtD
Halofantrine—Arrhythmia—Epirubicin—thyroid cancer	0.000972	0.00337	CcSEcCtD
Halofantrine—Visual impairment—Doxorubicin—thyroid cancer	0.00097	0.00336	CcSEcCtD
Halofantrine—Tinnitus—Doxorubicin—thyroid cancer	0.000938	0.00325	CcSEcCtD
Halofantrine—Back pain—Epirubicin—thyroid cancer	0.000916	0.00317	CcSEcCtD
Halofantrine—Chills—Doxorubicin—thyroid cancer	0.000903	0.00313	CcSEcCtD
Halofantrine—Arrhythmia—Doxorubicin—thyroid cancer	0.000899	0.00311	CcSEcCtD
Halofantrine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000878	0.00304	CcSEcCtD
Halofantrine—Malaise—Epirubicin—thyroid cancer	0.000854	0.00296	CcSEcCtD
Halofantrine—Back pain—Doxorubicin—thyroid cancer	0.000847	0.00294	CcSEcCtD
Halofantrine—Palpitations—Epirubicin—thyroid cancer	0.000837	0.0029	CcSEcCtD
Halofantrine—Cough—Epirubicin—thyroid cancer	0.000826	0.00286	CcSEcCtD
Halofantrine—Convulsion—Epirubicin—thyroid cancer	0.00082	0.00284	CcSEcCtD
Halofantrine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000813	0.00282	CcSEcCtD
Halofantrine—Arthralgia—Epirubicin—thyroid cancer	0.000806	0.00279	CcSEcCtD
Halofantrine—Chest pain—Epirubicin—thyroid cancer	0.000806	0.00279	CcSEcCtD
Halofantrine—Myalgia—Epirubicin—thyroid cancer	0.000806	0.00279	CcSEcCtD
Halofantrine—Discomfort—Epirubicin—thyroid cancer	0.000796	0.00276	CcSEcCtD
Halofantrine—Malaise—Doxorubicin—thyroid cancer	0.00079	0.00274	CcSEcCtD
Halofantrine—Confusional state—Epirubicin—thyroid cancer	0.000779	0.0027	CcSEcCtD
Halofantrine—Palpitations—Doxorubicin—thyroid cancer	0.000774	0.00268	CcSEcCtD
Halofantrine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000773	0.00268	CcSEcCtD
Halofantrine—Cough—Doxorubicin—thyroid cancer	0.000764	0.00265	CcSEcCtD
Halofantrine—Convulsion—Doxorubicin—thyroid cancer	0.000759	0.00263	CcSEcCtD
Halofantrine—Chest pain—Doxorubicin—thyroid cancer	0.000746	0.00258	CcSEcCtD
Halofantrine—Myalgia—Doxorubicin—thyroid cancer	0.000746	0.00258	CcSEcCtD
Halofantrine—Arthralgia—Doxorubicin—thyroid cancer	0.000746	0.00258	CcSEcCtD
Halofantrine—Discomfort—Doxorubicin—thyroid cancer	0.000737	0.00255	CcSEcCtD
Halofantrine—Anorexia—Epirubicin—thyroid cancer	0.000737	0.00255	CcSEcCtD
Halofantrine—Confusional state—Doxorubicin—thyroid cancer	0.000721	0.0025	CcSEcCtD
Halofantrine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000715	0.00248	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000704	0.00244	CcSEcCtD
Halofantrine—Paraesthesia—Epirubicin—thyroid cancer	0.000694	0.0024	CcSEcCtD
Halofantrine—Anorexia—Doxorubicin—thyroid cancer	0.000682	0.00236	CcSEcCtD
Halofantrine—Dyspepsia—Epirubicin—thyroid cancer	0.00068	0.00236	CcSEcCtD
Halofantrine—Decreased appetite—Epirubicin—thyroid cancer	0.000672	0.00233	CcSEcCtD
Halofantrine—Fatigue—Epirubicin—thyroid cancer	0.000666	0.00231	CcSEcCtD
Halofantrine—Constipation—Epirubicin—thyroid cancer	0.000661	0.00229	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000651	0.00226	CcSEcCtD
Halofantrine—Paraesthesia—Doxorubicin—thyroid cancer	0.000642	0.00222	CcSEcCtD
Halofantrine—Feeling abnormal—Epirubicin—thyroid cancer	0.000637	0.00221	CcSEcCtD
Halofantrine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000632	0.00219	CcSEcCtD
Halofantrine—Dyspepsia—Doxorubicin—thyroid cancer	0.000629	0.00218	CcSEcCtD
Halofantrine—Decreased appetite—Doxorubicin—thyroid cancer	0.000622	0.00215	CcSEcCtD
Halofantrine—Fatigue—Doxorubicin—thyroid cancer	0.000616	0.00214	CcSEcCtD
Halofantrine—Urticaria—Epirubicin—thyroid cancer	0.000614	0.00213	CcSEcCtD
Halofantrine—Constipation—Doxorubicin—thyroid cancer	0.000611	0.00212	CcSEcCtD
Halofantrine—Abdominal pain—Epirubicin—thyroid cancer	0.000611	0.00212	CcSEcCtD
Halofantrine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000589	0.00204	CcSEcCtD
Halofantrine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000585	0.00203	CcSEcCtD
Halofantrine—Urticaria—Doxorubicin—thyroid cancer	0.000568	0.00197	CcSEcCtD
Halofantrine—Abdominal pain—Doxorubicin—thyroid cancer	0.000565	0.00196	CcSEcCtD
Halofantrine—Asthenia—Epirubicin—thyroid cancer	0.000554	0.00192	CcSEcCtD
Halofantrine—Pruritus—Epirubicin—thyroid cancer	0.000547	0.00189	CcSEcCtD
Halofantrine—Diarrhoea—Epirubicin—thyroid cancer	0.000529	0.00183	CcSEcCtD
Halofantrine—Asthenia—Doxorubicin—thyroid cancer	0.000513	0.00178	CcSEcCtD
Halofantrine—Dizziness—Epirubicin—thyroid cancer	0.000511	0.00177	CcSEcCtD
Halofantrine—Pruritus—Doxorubicin—thyroid cancer	0.000506	0.00175	CcSEcCtD
Halofantrine—Vomiting—Epirubicin—thyroid cancer	0.000491	0.0017	CcSEcCtD
Halofantrine—Diarrhoea—Doxorubicin—thyroid cancer	0.000489	0.00169	CcSEcCtD
Halofantrine—Rash—Epirubicin—thyroid cancer	0.000487	0.00169	CcSEcCtD
Halofantrine—Dermatitis—Epirubicin—thyroid cancer	0.000487	0.00169	CcSEcCtD
Halofantrine—Headache—Epirubicin—thyroid cancer	0.000484	0.00168	CcSEcCtD
Halofantrine—Dizziness—Doxorubicin—thyroid cancer	0.000473	0.00164	CcSEcCtD
Halofantrine—Nausea—Epirubicin—thyroid cancer	0.000459	0.00159	CcSEcCtD
Halofantrine—Vomiting—Doxorubicin—thyroid cancer	0.000455	0.00157	CcSEcCtD
Halofantrine—Rash—Doxorubicin—thyroid cancer	0.000451	0.00156	CcSEcCtD
Halofantrine—Dermatitis—Doxorubicin—thyroid cancer	0.00045	0.00156	CcSEcCtD
Halofantrine—Headache—Doxorubicin—thyroid cancer	0.000448	0.00155	CcSEcCtD
Halofantrine—Nausea—Doxorubicin—thyroid cancer	0.000425	0.00147	CcSEcCtD
